Table 1.
Patients’ characteristics.
| N (%) | |
|---|---|
| Median age (range) | 56 (66; 30–92) |
| Median tumor size (range) | 12 (54.5; 0.5–55) |
| pT | |
| pTis | 78 (20.4%) |
| pT1a | 26 (6.8%) |
| pT1b | 87 (22.7%) |
| pT1c | 163 (4,5%) |
| pT2 | 29 (7.6%) |
| SLNB (sentinel lymph node biopsy) | 383 (100%) |
| Breast side | |
| Left | 201 (52.5%) |
| Right | 182 (4.,5%) |
| Immuno-histochemical molecular subtype | |
| DCIS | 81 (21.1%) |
| Luminal A | 193 (50.4%) |
| Luminal B HER2- | 87 (22.7%) |
| Luminal B HER2+ | 16 (4.2%) |
| HER2-enriched | 0 (0%) |
| Triple negative | 6 (1.6%) |
| Surgical margins | |
| Negative | 310 (81%) |
| Close/focally positive | 73 (19%) |
| Postoperative seroma | |
| Yes | 46 (12%) |
| No | 337 (88%) |
| Boost location | |
| Upper-outer | 222 (58%) |
| Upper-inner | 52 (13.6%) |
| Lower-outer | 54 (14%) |
| Lower-inner | 32 (8.4%) |
| Central | 23 (6%) |
| Chemotherapy/Targeted therapies | |
| Yes | 45 (11.7%) |
| No | 338 (88.3%) |
| Endocrine therapy | |
| Yes | 357 (93.2%) |
| No | 26(.,8%) |